ENERGIZE-T: A Global, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

Maria Domenica Cappellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Antonis Kattamis, Hui Shao(University of Louisville), Giovanna Cannas(Hôpital Edouard Herriot), Jayme L. Dahlin(Brigham and Women's Hospital), Sujit Sheth(Columbia University Irving Medical Center), Lauren Czapla(Agios Pharmaceuticals (United States)), John B. Porter(Royal London Hospital), Pencho Georgiev(University Multipurpose Hospital for Active Treatment "Sveti Georgi"), Khaled M. Musallam(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), David Benéitez(Vall d'Hebron Hospital Universitari), Bülent Antmen(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Kevin H.M. Kuo(University Health Network), Keely Gilroy(Agios Pharmaceuticals (United States)), Hanny Al‐Samkari(Harvard University), Sarah Gheuens(Biogen (United States)), Alì Taher(American University of Beirut Medical Center), Thomas D. Coates(Children's Hospital of Los Angeles), Vip Viprakasit(Siriraj Hospital), Andreas Glenthøj(University of Copenhagen), Kareem Osman(Agios Pharmaceuticals (United States)), Eduard J. van Beers(Utrecht University), Katrin Uhlig(Tufts Medical Center), Jeremie H. Estepp(St. Jude Children's Research Hospital)
Blood
November 5, 2024
Cited by 14


Related Papers